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Tandem BMT Meetings Workshop Descriptions
Mesenchymal Stem Cells: Do They Have a Role in Clinical Therapy?
(Workshop #1, Friday 2/13/04 2:00-3:30 PM)
Edwin M. Horwitz, MD, PhD
St. Jude Children’s Research Hospital
Memphis, TN
Mesenchymal stem cells (MSCs) are thought to reside within the marrow stroma in vivo and con-
tribute to the support of hematopoiesis. In vitro, MSCs are the ﬁbroblastic adherent cells obtained
from bone marrow that have the capacity to differentiate to bone, cartilage, and adipose tissue under
appropriate conditions. Although many studies of their antigenic determinants have been published, a
consensus phenotype to deﬁne MSCS has not been determined. The cells are typically deﬁned by their
morphology, adherence, and differentiation properties and, often, by the lack of hematopoietic antigen
expression.
MSCs have gained the attention of clinical investigators over the last few years in three speciﬁc arenas.
First, MSCs can differentiate to mesenchymal tissues, and possibly other tissues as well, suggesting the
potential for applications in stem cell therapy of nonhematopoietic tissues just as HSCs are stem cell
therapy for disorders of hematopoiesis. Indeed, MSCs have been used clinically in the treatment of genetic
bone disorders and metabolic storage diseases. Second, MSCs seem to possess unique immunologic
properties in vitro, suggesting that they may be able to evade immune recognition and suppress the
immune response, possibly across HLA barriers. These characteristics suggest that MSCs may be of great
value to modulate the immune system facilitating engraftment and/or reducing the risk of GVHD. Finally,
MSCs are readily transduced by retroviral vectors. These genetically modiﬁed MSCs may be able to serve
as vehicles to deliver cytokines or other agents to enhance engraftment, reduce GVHD, or facilitate other
antineoplastic therapies.
This workshop will focus on recent advances in the preclinical development and the clinical applications of
MSCs. We have a distinguished panel of experts to review our current knowledge, discussing previous successes
and failures of MSC therapy, and to propose the future direction of our ﬁeld. We encourage active contribu-
tions by all workshop participants in an effort to greater insights into the potential value of MSCs in clinical
therapy.
Medical Decision Making: What Do We Need to Know to Make Tough Choices?
(Workshop #2, Friday 2/13/04 2:00-3:30 PM)
Stephanie J. Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
and
Corey Cutler, MD, MPH, FRCP(C)
Dana-Farber Cancer Institute
Boston, MA
The role of allogeneic stem cell transplantation in the management of chronic phase chronic myeloid
leukemia (CML) has recently become controversial because of the promising results of imatinib mesylate
(Gleevec, Glivec). Using this clinical controversy as a framework for discussion, we hope to illustrate the
power and limitations of decision analysis, a method to formally integrate quantitative considerations of
patient characteristics, quality of life, attitudes towards risk, and likelihood of CML progression and
transplant success.
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Using a computer model, inputs from the literature, data from a survey of transplant physicians, and
audience participation, we will explore the “best” group recommendation under various scenarios, identify key
known and unknown variables that ought to drive recommendations, and discuss the pros and cons of using
decision analysis results for individual patient care.
New Approaches to the Treatment of Acute Graft-versus-Host Disease
(Workshop #3, Friday 2/13/04 2:00-3:30 PM)
Joseph H. Antin, MD
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
and
Daniel Weisdorf, MD
University of Minnesota
Minneapolis, MN
Acute graft-v-host disease is a hallmark and barrier to successful allogeneic transplantation. Although potent
prophylaxis can be devised, it is incompletely effective. Thus, therapy of acute GVHD is a necessary part of our
armamentarium. It is useful to conceptualize acute GVHD from the perspective of the graft. In this framework the
donor-derived immune-competent cells recognize host antigens that are interpreted as foreign and generate an
immunologic attack. The consequences of the activation of these cells are comparable to the response to a serious
infection. While usual GVHD therapy consisting of nonspeciﬁc immunologic blockade may reduce rash, diarrhea,
or bilirubin, the effects tend to be short-lived. Indeed, within this framework there is a predictable consequence: once
GVHD develops it is difﬁcult or impossible to interrupt without simultaneously paralyzing the response to infection.
This conundrum explains the cadre of effective drugs that may reduce the clinical manifestations of GVHD but fail
to improve survival as even responding patients go on to die of infection.
Discussions in this workshop will address ongoing and proposed trials of therapy for acute GVHD. The
discussions will include broad non-speciﬁc immunologic blockade, selective immunosuppression, and strategies
to prevent infection in the setting of the immunologic paralysis that accompanies GVHD and its treatment.
Animal Models for GVHD/GVL: How Relevant Are They for Clinical HCT?
(Workshop #4, Sunday 2/15/04 4:00-5:30 PM)
Marcel Van den Brink, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
and
Robert Korngold, PhD
Kimmel Cancer Center
Jefferson Medical College
Philadelphia, PA
Animal models are widely used to study the mechanisms related to the development of graft-versus-host
disease (GVHD) and graft-versus-leukemia (GVL) responses following allogeneic hematopoietic cell trans-
plantation (HCT). In this workshop we will discuss recent GVHD/GVL studies in animal models and their
relevance for clinical HCT. We will pay special attention to the differences between animal models and clinical
HCT and their implications for the transfer of preclinical animal data to the clinic. We will invite the authors
of related abstracts submitted for this year’s meeting to give short presentations and take part in the general
discussion.
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Statistical Issues in Bone Marrow Transplant Trials—Techniques for Competing
(Workshop #5, Sunday 2/15/04 4:00-5:30 PM)
John Klein, PhD
Medical College of Wisconsin
Milwaukee, WI
and
Mei-Jie Zhang, PhD
Medical College of Wisconsin
Milwaukee, WI
and
Ruta Bajorunaite, PhD
Marquette University
Milwaukee, WI
This workshop will focus on statistical methods for competing risk data. Competing risks arise in many
studies of BMT data, such as studies of treatment related mortality, relapse, graft-versus-host disease, and
engraftment. These events are often analyzed by in appropriate statistical methods. This workshop will consist
of three presentations by statistical researchers into methods for analyzing competing risks.
Prof. John Klein, Ph.D. of the Medical College of Wisconsin and the IBMTR/ABMTR/NMDP will discuss
methods for summarizing competing risks data. These methods include the cumulative incidence curve and the
crude hazard rate. When one is studying treatment related mortality, for example, the cumulative incidence is
the chance a patient has yet to die in remission while the crude hazard rate for treatment related mortality is the
rate at which patients in remission are dying. He will explain why analysis based on the Kaplan-Meier estimator
are not appropriate in most situations and can lead to misleading representations of the data.
Prof. Ruta Bajorunaite, Ph.D. of Marquette University and the IBMTR/ABMTR will present some recent
developments in statistical methods for directly comparing two or more cumulative incidence curves. She will
contrast methods that directly compare cumulative incidence curves with the more typically used log rank test
that compares the crude hazard rates.
Prof. Meijie Zhang, Ph.D. of the Medical College of Wisconsin and the IBMTR/ABMTR will discuss
recent developments in regression modeling for competing risks data. He will present two new methods based
on modeling either the cumulative incidence curve directly or on modeling a “hazard rate” obtained from the
cumulative incidence cure. These regression models are contrasted to the usual techniques for regression
models of competing risks data, the Cox proportional hazards model for the crude hazard rate.
Cytokines and Chemokines: Mechanisms of Mobilization
(Workshop #6, Sunday 2/15/04 4:00-5:30 PM)
Robert Negrin, MD
Stanford University Hospital
Stanford, CA
and
Edmund G. Waller, MD, PhD
Emory University
Atlanta, GA
In this workshop we will explore new approaches to the mobilization of cell products for autolgous and
allogeneic transplantation. Emphasis will be placed on new agents and mechanisms of mobilization. We will
focus on the mobilization of CD34 cells but also other cellular populations such as NK, T and dendritic cells
which could have important implications for outcome following transplantation. Strategies to collect sufﬁcient
numbers of stem and progenitor cells in the difﬁcult to mobilize patients will also be discussed. Newer agents
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which target novel chemokine receptors as well as the use of conventional growth factors and combinations of
growth factors will be explored. Efforts will be made to correlate ﬁndings of cellular composition in mobilized
products to eventual outcome with respect to engraftment, graft vs host disease, immune reconstitution and
eventual survival . The workshop will be in the format of short informal talks by investigators in the ﬁeld with
every effort made to enhance interaction and discussion.
Late Effects: Are We Doing Enough for Our Survivors?
Suggested surveillance strategies for late complications after hematopoietic cell transplantation
(Workshop #8, Tuesday 2/17/04 2:00-3:30 PM)
J. Douglas Rizzo, MD
Medical College of Wisconsin
Milwaukee, WI
and
Gerard Socie´, MD, PhD
Hopital Saint Louis
Paris, France
Successful management of early complications following hematopoietic cell transplantation (HCT), as well
as increased use of new transplant approaches in older adults has led to increasing numbers of patients surviving
without evidence of the disease for which the transplant was performed. Relapse remains a frequent compli-
cation, particularly for those who received autologous HCT. However, many patients and their non-transplant
care providers do not realize the increased risk of signiﬁcant post-transplant complications faced by long-term
survivors, in the absence of disease relapse. Patients may become fatigued by the frequency of medical contact
in the ﬁrst year after transplant, and avoid the medical system when possible. Others may believe their original
disease is cured, and their health status has returned to that of the “normal” population. Like the general
population, some overlook routine age-appropriate health screening recommendations. General health care
providers are occasionally unknowing facilitators of these decisions.
Although allogeneic and autologous HCT reduce immune competence of the host, immune impairment is
more substantial and durable in allogeneic recipients. Studies suggest that immune reconstitution is present at
6 months after transplantation in autologous survivors, but is generally just beginning in allogeneic survivors at
1 year after transplant. Chronic GVHD not only causes immune destruction of tissues, particularly skin, fascia
and mucosal tissues, but also extends the period of immunosuppression. The Centers for Disease Control has
recommended immunizations for survivors who have experienced immunologic recovery, however adherence
to these recommendations is not optimal. Endocrine effects include hypothyroidism, hypoadrenalism, gonadal
failure, and in children, growth abnormalities. Osteopenia and avascular necrosis can result from prolonged
steroid exposure, hormonal changes or radiation exposure. Major organ toxicity, secondary to chemotherapy,
radiotherapy, infectious or immune complications can affect the liver, lungs and kidneys. Deﬁciencies in organ
function may not become manifest until late after transplantation. Peripheral nervous symptoms are common,
and some patients complain of concentration and performance deﬁcits. In children, intellectual development
may be affected. While some patients experience enhanced psychologic growth after transplantation, others
experience depression and diminished quality of life. Perhaps most tragically, as many as 10% of long-term
survivors experience a second malignant condition.
The purpose of this interactive session will be to review the incidence of late effects experienced by HCT
recipients and their risk factors. Strategies to improve early diagnosis and management of these complications,
and raise awareness of survivors will be discussed. Forthcoming IBMTR/EBMT/ASBMT recommendations for
post-transplantation screening will be discussed.
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